WP
WHWK

Woodline Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Woodline Partners’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
436,614
+155,117
+55% +$645K 0.01% 840
2026
Q1 		$971K Buy
+281,497
New +$881K ﹤0.01% 889

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners's WHWK Position: Q2 2026 in Review

Woodline Partners increased its Whitehawk Therapeutics (WHWK) stake by 55% in Q2 2026, buying an estimated $645K and bringing the position to 436,614 shares worth $2M. The position accounts for 0.01% of the portfolio, ranked #840.

Woodline Partners first reported a position in WHWK in Q1 2026 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Woodline Partners held 436,614 shares of Whitehawk Therapeutics worth $2M as of Q2 2026.
  • Woodline Partners bought 155,117 Whitehawk Therapeutics shares in Q2 2026, an estimated $645K.
  • Whitehawk Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #840 holding.
  • Woodline Partners first reported a position in Whitehawk Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.